Expert Forum: Bladder Cancer - Episode 4
“There's unquestionably a real signal for…agents that are well tolerated that can be given for a long period of time,” says Sam S. Chang, MD, MBA.
In this video Sam S. Chang, MD, MBA, and Christopher B. Anderson, MD, MPH,discuss the recent FDA approvals of pembrolizumab (Keytruda) and nivolumab (Opdivo) and what they continue to learn from immunotherapy treatments. This discussion is part of a larger forum on bladder cancer with Chad R. Ritch, MD, MBA, FACS. Chang is a Patricia and Rodes Hart professor of urology and oncology at the Vanderbilt University Medical Center and chief surgical officer at the Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee. Ritch is an associate professor of urology and an associate director of UHealth International at the Miller School of Medicine, University of Miami, Florida. Anderson is an assistant professor of urology at Columbia University Irving Medical Center, Columbia University, New York City, New York.